SureTrader
Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Foxwoods Man, drkazmd65
Search This Board: 
Last Post: 2/22/2018 9:57:29 AM - Followers: 194 - Board type: Free - Posts Today: 4

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/

https://www.youtube.com/watch?v=auAihG3rtC4

Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
    The scientific, clinical, and commercial development of the medicine and
    CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
     
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  

    Teva Pharmaceuticals Industries Ltd.
     
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  

     
    Orient Europharma Co. Ltd.
     
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  

     
    IDC-GP Pharm LLC 
     
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  

     

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.




http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

 

SureTrader
CVM
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SureTrader
CVM News: Amended Statement of Ownership (sc 13g/a) 02/14/2018 05:58:14 PM
CVM News: CEL-SCI Corporation Reports First Quarter Fiscal 2018 Financial Results 02/12/2018 05:20:00 PM
CVM News: Quarterly Report (10-q) 02/12/2018 05:14:40 PM
CVM News: CEL-SCI to Present Tomorrow at 2018 BIO CEO & Investor Conference 02/12/2018 11:00:00 AM
CVM News: Securities Registration: Employee Benefit Plan (s-8) 02/09/2018 05:13:13 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#12411  Sticky Note Vienna, VA, January 3, 2018 -- CEL-SCI Foxwoods Man 01/03/18 08:19:00 AM
#7838  Sticky Note $CVM recent news/filings mick 01/18/16 02:09:58 PM
#5747  Sticky Note They keep coming!! Foxwoods Man 04/02/14 08:51:19 AM
#12803   totally agree Fox warfaretrader 02/22/18 09:57:29 AM
#12802   Agreed, My estimates based on the number of patients Spideyboy 02/22/18 08:58:17 AM
#12801   No equation needed. Around 350 +/- patients were Foxwoods Man 02/22/18 06:45:56 AM
#12800   Really? And what math makes sense? I assume learning curve 02/22/18 02:34:33 AM
#12799   Yup...that was discussed quite some time ago. The Foxwoods Man 02/21/18 07:04:23 AM
#12798   Before one tears apart the interview itself for learning curve 02/21/18 02:40:53 AM
#12797   I know I've been assuming that we wouldn't drkazmd65 02/20/18 07:59:42 PM
#12796   Did he really say we wouldn't have the Trustbaby 02/20/18 05:33:56 PM
#12795   New interview http://www.proactiveinvestors.com/companies/stocktube/8774/cel-sc trickledownfacists 02/20/18 02:54:45 PM
#12794   20 people/funds just bought 2.5m shares for $4.7m. Mtzzz 02/19/18 04:21:22 PM
#12793   Ok??? You didn’t follow the thread, but I learning curve 02/19/18 12:11:50 AM
#12792   You got it right... I'll give it to you. MikeDavis265 02/18/18 05:33:18 AM
#12791   Call yourself atomic bomb! I would fit better learning curve 02/17/18 03:43:44 AM
#12790   I’ll answer the riddle (for anybody that want learning curve 02/17/18 03:24:58 AM
#12789   This close to end of P3 and we steve2150 02/16/18 03:05:30 PM
#12788   No. It turns out he met some random Trustbaby 02/16/18 01:14:15 PM
#12787   So let me get this straight... two days warfaretrader 02/16/18 12:54:42 PM
#12786   The mm appears to agree. The bottom is learning curve 02/16/18 02:04:29 AM
#12785   Id advise go back on sideline if anybody learning curve 02/16/18 01:46:26 AM
#12784   I bought this stock in 2008 or 2009 lux1 02/14/18 03:40:33 PM
#12783   This board has gone downhill. Just ridiculous trickledownfacists 02/14/18 08:13:02 AM
#12782   Well, now we all know you aren’t the learning curve 02/14/18 02:30:36 AM
#12781   I apologize. I wasn’t listening well. Nor have learning curve 02/14/18 02:24:42 AM
#12780   And who would they reverse merger with? trickledownfacists 02/13/18 04:40:38 PM
#12779   I 'm saying this since the Watson's hiring. lux1 02/13/18 03:34:53 PM
#12778   Buy signal. Is what it is learning curve 02/13/18 03:02:30 PM
#12777   Wow I can't believe people are still talking Spike5 02/13/18 01:55:36 PM
#12776   NH has fallen from $12 to $3 mogman 02/13/18 12:44:07 PM
#12775   The new presentation is good. He reveals a Trustbaby 02/13/18 10:21:13 AM
#12774   Hopefully NH wasn’t one of his 3 public learning curve 02/13/18 02:38:39 AM
#12773   I’m sorry anybody who is hopeful. He learning curve 02/13/18 02:34:07 AM
#12772   Anybody do basic research on Robert e Watson? learning curve 02/13/18 02:27:00 AM
#12771   CEL-SCI Corporation Reports First Quarter Fiscal 2018 Financial Results drkazmd65 02/12/18 05:26:46 PM
#12770   Got some real people working on honing the MikeDavis265 02/12/18 03:38:28 PM
#12769   A new face in the space... that would MikeDavis265 02/12/18 09:04:42 AM
#12768   Some dude named Geert? Foxwoods Man 02/12/18 08:36:28 AM
#12767   Okay... who is the NEW CEO????? Not listed MikeDavis265 02/12/18 07:57:06 AM
#12766   Yeah, yeah, yeah....that’s it. They know of an learning curve 02/11/18 12:03:20 AM
#12765   I could only add that I don’t think learning curve 02/10/18 11:57:22 PM
#12764   Not trying to do anything. Just making a Foxwoods Man 02/10/18 12:43:38 PM
#12763   I look at it as if they can't Trustbaby 02/10/18 10:36:03 AM
#12762   I look at it as if they had Foxwoods Man 02/10/18 06:58:35 AM
#12761   Correct me if I am wrong, but that lightrock 02/09/18 05:09:59 PM
#12760   Yup...that's his thing...and he's good at it. Guess Foxwoods Man 02/09/18 02:56:34 PM
#12759   Continued inaccurate statements and not one has come true Lion33 02/09/18 02:25:14 PM
#12758   Doesn't the share price have to go DOWN Foxwoods Man 02/09/18 02:14:06 PM
#12757   Longs and shorts Geert has not shown his Dr_Biotechguru5 02/09/18 02:07:56 PM
#12756   Geert timed the Arbitration settlement news and positive Dr_Biotechguru5 02/09/18 01:41:08 PM
#12755   Nope. No "last" filing indicating ergomed sold shares. Mtzzz 02/09/18 01:21:02 PM
#12754   Fly On The Wall: CEL-SCI rewarded 50 Million Dr_Biotechguru5 02/09/18 01:10:59 PM
PostSubject